Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NBTX
stocks logo

NBTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 24.00 USD with a low forecast of 24.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 24.00 USD with a low forecast of 24.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 21.820
sliders
Low
24.00
Averages
24.00
High
24.00
Current: 21.820
sliders
Low
24.00
Averages
24.00
High
24.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
2025-11-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-11-04
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Nanobiotix to EUR 23 from EUR 20 and keeps a Buy rating on the shares. The firm believes the company's "non-dilutive" financing arrangement with HealthCare Royalty brings validation.
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
upgrade
2025-09-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-09-19
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Nanobiotix to EUR 13 from EUR 10 and keeps a Buy rating on the shares. The company announced positive results from the melanoma patient subset of cohort 3 of the ongoing Phase 1 Study 1100 evaluating JNJ-1900, the analyst tells investors in a research note.
Leerink
Jonathan Chang
Outperform
maintain
$9 -> $14
2025-09-18
Reason
Leerink
Jonathan Chang
Price Target
$9 -> $14
2025-09-18
maintain
Outperform
Reason
Leerink analyst Jonathan Chang raised the firm's price target on Nanobiotix to $14 from $9 and keeps an Outperform rating on the shares. Nanobiotix reported the first data update for NBTXR3 in anti-PD-1 resistant melanoma from its Phase I Study 1100, showing promising results that are supportive of further investigation in this indication, the analyst tells investors in a research note. Given the early nature of the data, Leerink continues to view this opportunity as upside to the firm's estimates.
Guggenheim
Michael Schmidt
Strong Buy
Maintains
$12 → $8
2025-04-04
Reason
Guggenheim
Michael Schmidt
Price Target
$12 → $8
2025-04-04
Maintains
Strong Buy
Reason
Guggenheim lowered the firm's price target on Nanobiotix to $8 from $12 and keeps a Buy rating on the shares. After the company reported FY24 earnings consistent with prior disclosures, the firm is updating its model to reflect second half results and remove assumptions for recurrent/metastatic head and neck squamous cell carcinoma.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nanobiotix SA (NBTX.O) is 162.12, compared to its 5-year average forward P/E of -7.29. For a more detailed relative valuation and DCF analysis to assess Nanobiotix SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.29
Current PE
162.12
Overvalued PE
68.36
Undervalued PE
-82.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.81
Current EV/EBITDA
-32.19
Overvalued EV/EBITDA
0.49
Undervalued EV/EBITDA
-12.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
62.89
Current PS
12.72
Overvalued PS
152.98
Undervalued PS
-27.21
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1048.78% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NBTX News & Events

Events Timeline

(ET)
2025-10-31
05:19:02
Nanobiotix secures $71M in royalty-based financing agreement with HealthCare Royalty
select
2025-10-24 (ET)
2025-10-24
05:10:25
Nanobiotix Offers Update on JNJ-1900 Following Johnson & Johnson Transition
select
2025-10-01 (ET)
2025-10-01
16:22:08
Nanobiotix Reveals Findings from JNJ-1900 Dose Escalation and Expansion Study Groups
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-25Benzinga
Semtech Reports Mixed Q3 Results, Alongside Zhihu, Nvidia, and Other Major Stocks Declining in Tuesday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures are down, with Dow futures decreasing by approximately 0.1% on Tuesday morning.

  • Semtech Corp Financial Results: Semtech Corp's shares fell 7.2% in pre-market trading after reporting mixed third-quarter results, with revenue of $267 million missing estimates but adjusted earnings of 48 cents per share exceeding expectations.

  • Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Arcus Biosciences (-6.7%), Nanobiotix (-6.2%), and Zhihu Inc (-5.2%).

  • Notable Stock Movements: Advanced Micro Devices and NVIDIA saw declines of 3.8% and 4.2%, respectively, following previous gains, indicating a broader trend of falling stock prices in the tech sector.

[object Object]
Preview
9.5
11-25Benzinga
Keysight Shares Rise Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Keysight Technologies Earnings Report: Keysight Technologies Inc. reported fourth-quarter earnings of $1.91 per share and revenue of $1.42 billion, surpassing analyst expectations, leading to a 14.8% increase in share price during pre-market trading.

  • Other Notable Gainers: Several stocks saw significant pre-market gains, including Icon Energy Corp (+33.4%), WeShop Holdings Limited (+23.1%), and Inno Holdings Inc (+23%), following positive trading sessions.

  • Stocks Experiencing Losses: MingZhu Logistics Holdings Ltd led the decliners with a 15.8% drop, alongside other companies like Prestige Wealth Inc (-11.2%) and Pasithea Therapeutics Corp (-11.1%) after previous gains.

  • Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both gainers and losers, along with specific financial results that influenced these movements.

[object Object]
Preview
7.5
11-25Newsfilter
Nanobiotix Closes $71 Million Royalty Financing with HCRx
  • Financing Milestone: Nanobiotix closed a non-dilutive royalty financing deal with HCRx, triggering an upfront payment of $50 million and an expected additional $21 million in one year, significantly strengthening the company's financial foundation for self-sustained long-term growth.
  • Clinical Progress: First data from a Phase 1 study of JNJ-1900 (NBTXR3) for esophageal cancer, sponsored by MD Anderson, has been presented, further validating the product's potential indications and likely advancing subsequent clinical development.
  • Sponsorship Transfer: The transfer of the NANORAY-312 study sponsorship for JNJ-1900 (NBTXR3) to Johnson & Johnson has been completed, ensuring operational control in most regions, which enhances clinical development efficiency and resource integration.
  • Product Development: The Curadigm Nanoprimer program is advancing with four new patent applications filed to support the development of proprietary internal pipeline products, alongside multiple material transfer agreements with external partners, indicating strong future market potential.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nanobiotix SA (NBTX) stock price today?

The current price of NBTX is 21.82 USD — it has increased 3.76 % in the last trading day.

arrow icon

What is Nanobiotix SA (NBTX)'s business?

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

arrow icon

What is the price predicton of NBTX Stock?

Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is 24.00 USD with a low forecast of 24.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nanobiotix SA (NBTX)'s revenue for the last quarter?

Nanobiotix SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Nanobiotix SA (NBTX)'s earnings per share (EPS) for the last quarter?

Nanobiotix SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Nanobiotix SA (NBTX)'s fundamentals?

The market is revising No Change the revenue expectations for NBTX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 150.80%.
arrow icon

How many employees does Nanobiotix SA (NBTX). have?

Nanobiotix SA (NBTX) has 108 emplpoyees as of December 05 2025.

arrow icon

What is Nanobiotix SA (NBTX) market cap?

Today NBTX has the market capitalization of 1.05B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free